Mid-cap Healthcare company Novavax has moved -0.7% so far today on a volume of 2,141,084, compared to its average of 6,332,166. In contrast, the S&P 500 index moved 1.4%.
Novavax trades -86.55% away from its average analyst target price of $77.67 per share. The 6 analysts following the stock have set target prices ranging from $13 to $207, and on average have given Novavax a rating of hold.
Anyone interested in buying NVAX should be aware of the facts below:
-
Novavax's current price is -80.4% below its Graham number of $53.3, which implies the stock has a margin of safety
-
Novavax has moved -94.3% over the last year, and the S&P 500 logged a change of -18.6%
-
Based on its trailing earning per share of -17.51, Novavax has a trailing 12 month Price to Earnings (P/E) ratio of -0.6 while the S&P 500 average is 15.97
-
NVAX has a forward P/E ratio of -2.0 based on its forward 12 month price to earnings (Eps) of $-5.31 per share
-
The company has a price to earnings growth (PEG) ratio of -0.03 — a number near or below 1 signifying that Novavax is fairly valued compared to its estimated growth potential
-
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.
-
Based in Gaithersburg, the company has 1,541 full time employees and a market cap of $888,113,280.
